Relief Therapeutics Holding AG
RLFTF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $1,218 | $2,763 | $5,654 | $3,010 |
| % Growth | -55.9% | -51.1% | 87.8% | – |
| Cost of Goods Sold | $599 | $1,013 | $1,562 | $8,150 |
| Gross Profit | $619 | $1,750 | $4,092 | -$5,140 |
| % Margin | 50.8% | 63.3% | 72.4% | -170.8% |
| R&D Expenses | $580 | $624 | $733 | $395 |
| G&A Expenses | $1,083 | $7,225 | $2,017 | $1,929 |
| SG&A Expenses | $3,980 | $3,931 | $5,899 | $2,629 |
| Sales & Mktg Exp. | $225 | $190 | $398 | $758 |
| Other Operating Expenses | $484 | $12,102 | $1,438 | $94 |
| Operating Expenses | $5,044 | $16,657 | $8,070 | $3,118 |
| Operating Income | -$4,425 | -$14,907 | -$3,978 | -$99,182 |
| % Margin | -363.3% | -539.5% | -70.4% | -3,295.1% |
| Other Income/Exp. Net | -$79 | -$452 | -$19 | $51,640 |
| Pre-Tax Income | -$4,504 | -$15,359 | -$3,997 | -$47,542 |
| Tax Expense | $26 | -$2,797 | $560 | -$5,860 |
| Net Income | -$4,478 | -$12,562 | -$4,557 | -$41,682 |
| % Margin | -367.7% | -454.7% | -80.6% | -1,384.8% |
| EPS | -0.36 | -1 | -0.36 | -3.32 |
| % Growth | 64% | -177.8% | 89.2% | – |
| EPS Diluted | -0.36 | -1 | -0.36 | -3.32 |
| Weighted Avg Shares Out | 12,553 | 12,540 | 12,554 | 12,540 |
| Weighted Avg Shares Out Dil | 12,553 | 12,540 | 12,554 | 12,540 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $30 | $158 | $468 |
| Interest Expense | $0 | $133 | $82 | $241 |
| Depreciation & Amortization | $504 | $1,123 | $1,438 | $1,614 |
| EBITDA | -$4,015 | -$14,040 | -$2,540 | -$6,644 |
| % Margin | -329.6% | -508.1% | -44.9% | -220.7% |